Bratschi Guides Precipart Shareholders in KKR Investment Deal

Swiss law firm Bratschi played a pivotal role in advising the shareholders of Precipart, a prominent manufacturer specializing in precision components for the medical device and aerospace sectors, concerning a significant investment from KKR.

KKR is investing through its Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth healthcare related companies. KKR has a long track record of supporting healthcare companies globally, having committed over $20 billion to the sector since 2004. Founded in 1950 by the Laubscher family, they will retain  a significant minority ownership stake in the company.

Leading the legal team were partner Simon Osterwalder, (M&A, pictured left), and partner Michael Barrot (tax, pictured right), supported by a seasoned group of professionals. Etienne Gard (partner, M&A), Barbara Jecklin (partner, corporate finance), Markus Huber and Kerem Altay (both associates. tax), and Stephanie Caprani (associate, M&A), were integral members of the team.